Company intelligence / Profile preview

VivaVision Biotech

Wenzhou City, Zhejiang Province, Chinavivavisionbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

VivaVision Biotech is a clinical-stage pharmaceutical company focused on developing best-in-class and first-in-class therapies for ocular diseases. Its lead asset, VVN001 for dry eye syndrome, has completed successful Phase II trials in both China and the US. Additional clinical assets target glaucoma/ocular hypertension and non-infectious uveitis. The company maintains an active pipeline of small molecule drugs addressing significant unmet needs in ophthalmology.

Therapeutic areas: DermatologyOphthalmology
Modalities: Small moleculesChemical drugsBiological productsSynthetic peptides
Industry: Biotech

Drug pipeline

7 assets

VVN001

6 more assets in the full pipeline.

Request access →

Partnerships

Incubated/invested by Viva BioInnovator/Viva Biotech Holdings.

Beyond the preview

Go deeper on VivaVision Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VivaVision Biotech.

Explore the full profile